The Scientist

» drug development

Most Recent

image: Allergan Set to Buy Vitae

Allergan Set to Buy Vitae

By | September 16, 2016

The Irish drugmaker has made a $639 million dollar offer to buy the US-based biopharma.

0 Comments

image: The Challenges of Rare-Disease Research

The Challenges of Rare-Disease Research

By | September 1, 2016

With few resources and hesitant investors, basic scientists must rely on clinicians, patient advocates, and their own keen eye for biological connections.

0 Comments

image: Pfizer to Buy Medivation for $14 Billion

Pfizer to Buy Medivation for $14 Billion

By | August 22, 2016

The pharma giant is purchasing the San Francisco–based cancer drugmaker to boost its oncology portfolio.

0 Comments

image: The Growth of Iowa Biotech

The Growth of Iowa Biotech

By | August 1, 2016

The state’s industry draws inspiration from medicine as well as agriculture.

1 Comment

image: Mystery Mechanisms

Mystery Mechanisms

By | July 29, 2016

Scientists still don’t know exactly how some commonly used drugs work. Here’s a look at three such compounds.

0 Comments

The change should allow patients with fatal illnesses easier access to experimental drugs, but gaining permission from drug companies remains the biggest challenge.

0 Comments

Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.

1 Comment

image: Toward Targeted Therapies for Autoimmune Disorders

Toward Targeted Therapies for Autoimmune Disorders

By | June 1, 2016

Training the immune system to cease fire on native tissues could improve outcomes for autoimmune patients, but clinical progress has been slow.

1 Comment

image: Pfizer Scoops Anacor for $5.3 Billion

Pfizer Scoops Anacor for $5.3 Billion

By | May 17, 2016

The acquisition-hungry pharmaceutical firm is purchasing the California-based eczema gel maker.

0 Comments

image: Another Fatal-Disease Drug in Limbo

Another Fatal-Disease Drug in Limbo

By | April 26, 2016

A federal advisory panel votes against Sarepta Therapeutics’s treatment for Duchenne muscular dystrophy.

0 Comments

Popular Now

  1. Consilience, Episode 3: Cancer, Obscured
  2. RNAi’s Future in Drug-Target Screening
    News Analysis RNAi’s Future in Drug-Target Screening

    A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool? 

  3. A History of Screening for Natural Products to Fight Cancer
  4. Streakers, Poopers, and Performers: The Wilder Side of Wildlife Cameras
AAAS